Can you provide examples of combined oral contraceptive pills (OCP) with their brand names and generic formulations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Combined Oral Contraceptive Pills: Examples with Brand Names

Combined oral contraceptives (COCs) contain an estrogen component (typically ethinyl estradiol ≤50 μg or natural estrogens) combined with a progestin, available in multiple formulations and brand names 1.

First-Line COC Formulations

Pills containing levonorgestrel or norethindrone (first/second generation progestins) combined with ethinyl estradiol 35 μg or less are considered first-line options 2. These formulations offer:

  • Proven contraceptive efficacy
  • Relatively low risk of venous thromboembolism
  • Cost-effectiveness

Common Brand Examples by Progestin Type:

Levonorgestrel-containing COCs:

  • Levlen (ethinyl estradiol 30 μg/levonorgestrel 150 μg)
  • Nordette (ethinyl estradiol 30 μg/levonorgestrel 150 μg)
  • Seasonale (extended cycle formulation)
  • Seasonique (extended cycle formulation)

Norethindrone-containing COCs:

  • Ortho-Novum (various formulations with ethinyl estradiol 35 μg)
  • Necon (ethinyl estradiol 35 μg/norethindrone)
  • Loestrin (ethinyl estradiol 20-30 μg/norethindrone acetate)

Newer Generation COCs

Third and fourth generation progestins were developed to reduce androgenic side effects 1, 3:

Desogestrel-containing:

  • Desogen (ethinyl estradiol 30 μg/desogestrel 150 μg)
  • Ortho-Cept (ethinyl estradiol 30 μg/desogestrel 150 μg)

Drospirenone-containing (fourth generation with anti-mineralocorticoid activity):

  • Yasmin (ethinyl estradiol 30 μg/drospirenone 3 mg)
  • Yaz (ethinyl estradiol 20 μg/drospirenone 3 mg)

Dienogest-containing:

  • Natazia/Qlaira (estradiol valerate/dienogest - contains natural estrogen) 4

Natural Estrogen-Containing COCs

Two formulations with natural estrogens have been approved 4:

  • Natazia/Qlaira (estradiol valerate/dienogest) - most widely available
  • Femilar (estradiol valerate/cyproterone acetate) - limited approval in Finland only

These natural estrogen formulations were developed to potentially reduce VTE and cardiovascular risks compared to ethinyl estradiol, though Phase IV trials are still needed to confirm these benefits 1.

Dosing Regimens Available

COCs come in multiple regimen types 1:

  • Monophasic: Same hormone dose daily (e.g., most formulations listed above)
  • Multiphasic: Varying weekly doses (e.g., Ortho-Novum 7/7/7)
  • Cyclic: 21-24 active pills + 7-4 placebo days (traditional)
  • Extended cycle: 84 active pills + 7 placebo days (e.g., Seasonale, Seasonique)
  • Continuous: Active pills without placebo intervals

Key Clinical Considerations

Blood pressure measurement is required before CHC initiation 5. If started >5 days after menses, backup contraception (barrier methods) is needed for 7 days 5.

Common pitfall: The vast majority of currently available COCs contain ≤50 μg ethinyl estradiol, as higher doses were associated with unacceptable cardiovascular and VTE risks 1, 6. Never prescribe formulations exceeding this threshold.

Individualization strategy: While first-line options (levonorgestrel or norethindrone with low-dose ethinyl estradiol) should be prescribed initially, newer generation progestins may be considered for women experiencing androgenic side effects like acne 3, 2.

References

Research

Choosing a combined oral contraceptive pill.

Australian prescriber, 2015

Research

Combined oral contraceptives: update recommendations of the Latin American contraceptive association.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2023

Research

An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012

Guideline

u.s. selected practice recommendations for contraceptive use, 2024.

MMWR Recommendations and Reports, 2024

Related Questions

What are the key principles of pre‑operative assessment and the recommended approach to common post‑operative complications according to Canadian guidelines?
How should a 23-year-old male presenting with dysuria and urethral discharge be evaluated and treated?
In a 15‑year‑old male with persistent left lower‑quadrant abdominal tenderness and bruising, right‑sided back pain radiating to the ribs, and new left great‑toe stabbing pain with tingling after a recent appendectomy, what imaging studies and medical management are indicated?
How should a 24‑week pregnant woman with an 18‑lb weight gain be evaluated and managed?
In a 23‑year‑old woman with dysuria, burning and tearing sensation during and after intercourse, should she be referred to a gynecologist first or a urologist?
What are the recommended treatments for fatigue in a patient with respiratory failure?
What is the most appropriate analgesic for moderate to severe ovarian cancer pain?
What is the appropriate management of fatigue due to respiratory failure in a skilled‑nursing facility resident?
What is the recommended dosing and administration of naloxone 1 mg intravenous (IV) push for a patient with suspected opioid overdose?
After total thyroidectomy for papillary thyroid carcinoma six years ago, with current low‑normal TSH, stable mildly elevated thyroglobulin levels, negative neck imaging, and a 4‑mm Lung‑RADS 2 juxtaplural right upper‑lobe nodule, is there evidence of recurrent disease?
Can a Depakote (valproic acid) 125 mg extended‑release (EC) capsule be opened and the contents sprinkled for administration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.